GC
RVMD icon

Grimes & Company’s Revolution Medicines RVMD Stock Holding History

Grimes & Company’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
+2,369
New +$346K 0.01% 330

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Grimes & Company's RVMD Position: Q2 2026 in Review

Grimes & Company opened a new position in Revolution Medicines (RVMD) in Q2 2026: 2,369 shares worth $444K. The stake represents 0.01% of the portfolio and ranks #330 among its holdings.

689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Grimes & Company held 2,369 shares of Revolution Medicines worth $444K as of Q2 2026.
  • Revolution Medicines was a new Grimes & Company position in Q2 2026.
  • Revolution Medicines made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #330 holding.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.